INBX

Business Context and Reporting Period

Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and nine months ended September 30, 2024
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company focused on oncology. The reporting period is defined by a major corporate restructuring: on May 30, 2024, the company completed a separation from its former parent (Inhibrx, Inc.) and a merger with Aventis Inc. (a Sanofi subsidiary). The former parent acquired the INBRX-101 asset, while Inhibrx Biosciences retained its oncology pipeline, including ozekibart (INBRX-109) and INBRX-106, becoming a stand-alone public entity.

Key Financial Metrics

Note: 9M 2024 Net Income includes a non-cash gain of $2.02 billion related to the separation transaction.

Material Changes vs. Prior Period

• Transaction Gain: The nine months ended September 30, 2024, reported a net income of $1.74 billion, driven entirely by a $2.02 billion non-cash gain recognized upon the separation and merger. This contrasts with a net loss of $147.8 million in the same period in 2023.
• Debt Extinguishment: Long-term debt of approximately $207 million (principal and fees) was assumed by the Acquirer (Sanofi/Aventis) during the merger. Consequently, interest expense dropped to zero for Q3 2024, compared to $8.1 million in Q3 2023.
• Expense Volatility: General and Administrative (G&A) expenses surged to $111.2 million for the nine months ended September 2024 (vs. $21.5 million in 2023). This increase was primarily due to $68.1 million in transaction costs and $15.2 million in accelerated stock-based compensation related to the merger.
• R&D Growth: R&D expenses increased 56% year-over-year for the nine-month period ($170.4M vs $109.5M), driven by expanded clinical trials for ozekibart and INBRX-106, and increased contract manufacturing costs.

Guidance, Outlook, and Risks

• Liquidity: As of September 30, 2024, the company held $196.3 million in cash. Management believes this is sufficient to fund operations for at least 12 months. Future funding may require equity offerings, debt, or strategic collaborations.
• Clinical Pipeline Outlook:
  • ozekibart (INBRX-109): Phase 2 data for chondrosarcoma and Ewing sarcoma/colorectal cancer is expected in mid-2025.
  • INBRX-106: A seamless Phase 2/3 trial in Head and Neck Squamous Cell Carcinoma (HNSCC) was initiated in June 2024. Initial Phase 2 data is expected in the second half of 2025.
• Risks and Contingencies:
  • Legal Proceedings: The company recently won a trade secrets lawsuit filed by I-Mab Biopharma (November 2024), with the jury rejecting all allegations. No liability was recorded.
  • Forward-Looking Statements: Significant risks include the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to raise additional capital.

Investor Verification Checklist

• Transaction Accounting: Verify the treatment of the $2.02 billion gain as a non-cash item and its impact on the accumulated deficit reduction.
• Cash Burn Rate: Assess the sustainability of the $196.3 million cash balance against the elevated R&D and G&A burn rates post-merger.
• Debt Status: Confirm the complete extinguishment of the $200 million Oxford Finance loan and the absence of remaining covenants.
• Stock-Based Compensation: Review the impact of the accelerated vesting of options ($39.3 million recognized) and the new 2024 Equity Plan on future expense.
• Related Party Transactions: Monitor the Transition Services Agreement with the Former Parent/Sanofi for ongoing revenue or cost reimbursements.